Ajanta Pharma Ltd. News and Updates

Name: Latest research reports of Ajanta Pharma Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Ajanta Pharma Ltd.
Rating: 3
Author: ICICI Securities Limited

Keep track of all breaking news on Ajanta Pharma Ltd. from all sources in a single place.

Load latest

Ajanta Pharma Ltd.

01 Feb 2019

2398.40

-3.49%

Ajanta Pharmaceuticals

Hold: Ajanta Pharma Ltd.

Recommendation Target

ICICI Securities Limited

Ajanta Pharma's Q3FY19 results were below I-direct estimates on all fronts mainly due to lower-than-exacted export formulation sales Revenues declined 17.4% YoY to | 485.1 crore (I-direct estimate: | 522.6 crore) due to 26.7% YoY decline in export formulations to...

Ajanta Pharma Ltd.'s price crossed below 30Day SMA today

Ajanta Pharma Ltd.

31 Jan 2019

2398.40

-3.49%

Blockchain start-up InfiniChains raises $2.4 mn from Ajanta Pharma founder

Business Standard

The firm uses blockchain technology for counterfeit prevention, traceability and authentication of origin of materials in various industries such as fashion and food.

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

31 Jan 2019

2398.40

-3.49%

Share buyback nod fails to lift Ajanta Pharma; falls 7% on weak Q3 results

Business Standard

The stock dipped 7 per cent to Rs 1,016 on BSE after the company's consolidated net profit more-than-halved at Rs 67 crore in Q3FY19, due to lower sales.

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

30 Jan 2019

2398.40

-3.49%

Ajanta Pharma board okays buyback at 1,300 a share

Business Line

Promoters express interest to participate'

Ajanta Pharma Ltd. has lost -27.86% in the last 6 Months

Ajanta Pharma Ltd.

06 Jan 2019, 05:00PM

2398.40

-3.49%

Ajanta Pharma: Relief in sight

Business Line

The company's long-term prospects seem robust, given its strong domestic presence

Ajanta Pharma Ltd.'s price crossed below 30Day SMA today

Ajanta Pharma Ltd.

05 Jan 2019, 07:32PM

2398.40

-3.49%

Ajanta Pharma: Relief in sight

Business Line

The company's long-term prospects seem robust, given its strong domestic presence

Ajanta Pharma Ltd. has lost -27.86% in the last 6 Months

Ajanta Pharma Ltd.

03 Dec 2018

2398.40

-3.49%

Top buy, sell, hold ideas from D-St experts

Economic Times

Ajanta Pharma is a 'Buy' call with a target price of Rs 1225 and a stop loss of Rs 1140.

Ajanta Pharma Ltd. has an average target of 2987.67 from 3 brokers.

Ajanta Pharma Ltd.

03 Nov 2018

2398.40

-3.49%

Ajanta Pharma Ltd Q2FY19 results Comment

Results Update: Ajanta Pharma Ltd.

HDFC Securities

Ajanta Pharma Ltd Q2FY19 results Comment Revenue increased by 6.48% to Rs. 544.11 Cr in Q2FY19 when compared to the previous quarter. Also, it rose by 0.69% when compared with Q2FY18

Ajanta Pharma Ltd.'s price crossed below 30Day SMA today

Ajanta Pharma Ltd.

01 Nov 2018

2398.40

-3.49%

Ajanta Pharma-Result Update

Buy: Ajanta Pharma Ltd.

Reliance Securities

Ajanta Pharma (AJP) has delivered a better-than-expected performance on all operational metrics in 2QFY19 led by strong sales growth in Asia/US as well as lower-than-expected decline in Africa sales. Domestic business reported flat growth due to high YoY base led by channel re-filling post GST roll-out. Despite marginal sales growth, AJP's EBITDA de-grew by 9.5% YoY to Rs1.7bn on account of higher staff and other operating expenditure, owing to which EBITDA margin contracted by 345bps YoY to 30.5%. However, AJP's gross margin expanded by 255bps YoY to 82.4% due to better product-mix. Led by higher taxes, PAT de-grew by 4.9% YoY to Rs1.3bn. The Company is expected to file 10-12 ANDAs with the USFDA in FY19E. LPC maintained...

Number of FII/FPI investors increased from 346 to 373 in Dec 2024 qtr.

Ajanta Pharma Ltd.

01 Nov 2018

2398.40

-3.49%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Recommendation Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Ajanta Pharma's Q2FY19 results were above I-direct estimates on all fronts mainly on account of a beat in export sales and higher other income. Revenues grew 0.7% YoY to | 544.1 crore. Muted growth was mainly due to the high base of restocking in domestic market post GST implementation and shrinking in African tender business. Beat vis--vis I-direct estimates was due to strong US sales EBITDA margins contracted 345 bps YoY to 30.5% (I-direct...